Estrella Immunopharma(ESLA.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Estrella Immunopharma
ESLA.US
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company’s lead product candidate is EB103, which is in clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It has a collaborative agreement with Eureka and Imugene Limited for the development of solid tumor treatments using Imugene’s product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc.
1.970 T
ESLA.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Estrella Immunopharma Faces Nasdaq Delisting Risk Over Missed Annual Meeting

    Estrella Immunopharma Inc. faces potential delisting from Nasdaq due to non-compliance with Listing Rule 5620(a), which mandates annual shareholder meetings. The company has 45 days to submit a compliance plan and intends to hold its meeting in April 2026. While the notice does not immediately affect trading, there is no assurance that Nasdaq will accept the compliance plan or that the company will regain compliance within any extension period.

    Reuters·
    US
    ESLA
    +4.90%
    Reuters·
    US
    ESLA
    +4.90%

    Estrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Private Placement | ESLA Stock News

    Estrella Immunopharma, Inc. has closed an $8.0 million registered direct offering and concurrent private placement, issuing 4,063,290 shares of common stock and 1,000,000 pre-funded warrants. The offering price was $1.58 per share, with pre-funded warrants exercisable immediately. The funds will support the company's clinical objectives, particularly advancing its lead program, EB103, through Phase II trials. Aegis Capital Corp. acted as the exclusive placement agent. The securities were offered under a shelf registration statement and are available only to accredited investors.

    StockTitan·
    US
    ESLA
    +4.90%
    StockTitan·
    US
    ESLA
    +4.90%

    Estrella Immunopharma Announces $8.0 Million Registered Direct Offering

    Jan 5 (Reuters) - Estrella Immunopharma Inc:* ESTRELLA IMMUNOPHARMA, INC. ANNOUNCES $8.0 MILLION REGISTERED DIRECT OFFERING AND CONCURRENT PRIVATE PLACEMENT PRICED AT-THE-MARKET UNDER NASDAQ RULES Source text: Further company coverage:

    Reuters·
    US
    ESLA
    +4.90%
    Reuters·
    US
    ESLA
    +4.90%

    Estrella Immunopharma Raises $8 Million in Private Placement of Shares and Warrants

    Estrella Immunopharma Inc. has raised $8 million through a private placement of unregistered securities to a healthcare-focused institutional investor. The transaction includes pre-funded warrants and PIPE common warrants, which cannot be resold in the U.S. without registration. The company will file registration statements for the resale of common stock and shares from the warrants as part of a registration rights agreement with the investor.

    Reuters·
    US
    ESLA
    +4.90%
    Reuters·
    US
    ESLA
    +4.90%

    Estrella Immunopharma Offers Up To 2.5 Mln Shares For Resale By Selling Stockholders

    Estrella Immunopharma Inc :ESTRELLA IMMUNOPHARMA INC - OFFERS UP TO 2,541,206 SHARES FOR RESALE BY THE SELLING STOCKHOLDERS - SEC FILING

    Reuters·
    US
    ESLA
    +4.90%
    Reuters·
    US
    ESLA
    +4.90%
    © 2026 Longbridge｜Disclaimer